112 related articles for article (PubMed ID: 34929996)
1. Evaluation of MACK-3 parameters, metabolic and fibrotic characteristics of non-alcoholic fatty liver disease patients with hypertension.
Babak O; Lapshyna K; Prosolenko K; Chernyak A; Goptsiy O
Minerva Gastroenterol (Torino); 2022 Dec; 68(4):415-420. PubMed ID: 34929996
[TBL] [Abstract][Full Text] [Related]
2. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients.
Canivet CM; Zheng MH; Qadri S; Vonghia L; Chuah KH; Costentin C; George J; Armandi A; Adams LA; Lange NF; Blanchet O; Moal V; Younes R; Roux M; Chan WK; Sturm N; Eslam M; Bugianesi E; Wang Z; Dufour JF; Francque S; Yki-Järvinen H; Zheng KI; Boursier J
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3097-3106.e10. PubMed ID: 37031715
[TBL] [Abstract][Full Text] [Related]
5. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH.
Boursier J; Anty R; Vonghia L; Moal V; Vanwolleghem T; Canivet CM; Michalak S; Bonnafous S; Michielsen P; Oberti F; Iannelli A; Van Gaal L; Patouraux S; Blanchet O; Verrijken A; Gual P; Rousselet MC; Driessen A; Hunault G; Bertrais S; Tran A; Calès P; Francque S
Aliment Pharmacol Ther; 2018 May; 47(10):1387-1396. PubMed ID: 29577364
[TBL] [Abstract][Full Text] [Related]
6. FICK-3 Score Combining Fibrosis-4, Insulin Resistance and Cytokeratin-18 in Predicting Non-alcoholic Steatohepatitis in NAFLD Egyptian Patients.
Mohammed MA; Omar NM; Mohammed SA; Amin AM; Gad DF
Pak J Biol Sci; 2019 Jan; 22(10):457-466. PubMed ID: 31930835
[TBL] [Abstract][Full Text] [Related]
7. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
8. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
[TBL] [Abstract][Full Text] [Related]
9. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
11. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
12. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
[TBL] [Abstract][Full Text] [Related]
13. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
[TBL] [Abstract][Full Text] [Related]
15. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
16. SHOULD ROUTINE LIVER BIOPSY BE CONSIDERED IN BARIATRIC SURGICAL PRACTICE? AN ANALYSIS OF THE LIMITATIONS OF NON-INVASIVE NAFLD MARKERS.
Concon MM; Gestic MA; Utrini MP; Chaim FDM; Chaim EA; Cazzo E
Arq Gastroenterol; 2022; 59(1):110-116. PubMed ID: 35442320
[TBL] [Abstract][Full Text] [Related]
17. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
[TBL] [Abstract][Full Text] [Related]
18. [ANTHROPOMETRIC CHARACTERISTICS AND PARAMETERS OF LIPID-CARBOHYDRATE METABOLISM IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTENSION DEPENDING ON THE DEGREE OF HEPATIC STEATOSIS].
Babak О; Bashkirova А
Georgian Med News; 2018 Nov; (284):59-65. PubMed ID: 30618391
[TBL] [Abstract][Full Text] [Related]
19. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
[TBL] [Abstract][Full Text] [Related]
20. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease.
Fujii H; Imajo K; Yoneda M; Nakahara T; Hyogo H; Takahashi H; Hara T; Tanaka S; Sumida Y; Eguchi Y; Chayama K; Nakajima A; Nishimoto N; Kawada N;
J Gastroenterol Hepatol; 2019 Aug; 34(8):1390-1395. PubMed ID: 30600551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]